<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770013</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/182/18</org_study_id>
    <nct_id>NCT03770013</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Clonidine for Transversus Abdominis Plane Block in Patients Undergoing Elective Caesarean Section</brief_title>
  <official_title>Role of Co-administered Dexmedetomidine Or Clonidine With Bupivacaine for Transversus Abdominis Plane Block in Patients Undergoing Elective Caesarean Section: A Randomized, Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim to study the efficacy of co-administered Dexmedetomidine Or Clonidine with Bupivacaine
      and that of bupivacaine 0.25% alone for Transversus Abdominis Plane (TAP) Block for
      Postoperative Analgesia in Patients Undergoing Elective Caesarean Section.

        -  Group 1: bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml
           each side) was used for the TAP block.)

        -  Group 2: 20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml
           each side) was used for the TAP

        -  Group3: bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used
           for the TAP A prospective Randomized Interventional double-blind study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women, following Caesarean delivery, have even more compelling reasons to receive optimal
      post-operative pain relief, for improved maternal and neonatal well-being. Also, adequate
      pain relief helps the patient to ambulate early and prevent any thrombotic incidents .
      Dexmedetomidine, an imidazole compound, is the pharmacologically active dextroisomer of
      medetomidine that displays specific and selective Î± 2-adrenoceptor agonist activity and
      causes sedation, analgesia without any delirium, or respiratory depression. The mechanism of
      action is unique and differs from those of currently used agents, including clonidine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective Randomized Interventional double-blind study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The time for first rescue analgesia after the TAP block</measure>
    <time_frame>24 hours post operative</time_frame>
    <description>calculation the time needed for first rescue analgesia after the TAP block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of rescue analgesia</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>calculation of Total dose of rescue analgesia required in 24 h post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Adverse effects like pruritus, nausea and vomiting, hypotension, bradycardia, and sedation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>bupivacaine 0.25% and Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine and clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine</intervention_name>
    <description>bupivacaine 0.25% a total volume of 40 ml (20 ml each side</description>
    <arm_group_label>bupivacaine 0.25% and Dexmedetomidine</arm_group_label>
    <arm_group_label>bupivacaine and clonidine</arm_group_label>
    <arm_group_label>bupivacaine and placebo</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 0.5 mcg/kg</description>
    <arm_group_label>bupivacaine 0.25% and Dexmedetomidine</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clonidine</intervention_name>
    <description>1ug/kg clonidine</description>
    <arm_group_label>bupivacaine and clonidine</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>add placebo 9normal saline)</description>
    <arm_group_label>bupivacaine and placebo</arm_group_label>
    <other_name>placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  parturients scheduled to undergo cesarean section under spinal anesthesia

        Exclusion Criteria:

          -  Patients who refused spinal anesthesia

          -  women with chronic pelvic pain or on chronic morphine use

          -  history of drug allergy

          -  coagulation disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients Undergoing Elective Caesarean Section.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f sallam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f sallam, md</last_name>
    <phone>01022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aswan University</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hany f sallam, md</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.ed.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla w Shady, md</last_name>
      <phone>1019240504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bupivacaine</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Clonidine</keyword>
  <keyword>Transversus Abdominis Plane Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

